Merck & Co.
AWARDS
NEWS
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
The U.S. Attorney’s Office was busy indicting nine people for charges related to insider trading. Some charges were unrelated, but three were specific to the biopharma industry.
Merck’s Phase III trial studying Keytruda (pembrolizumab) for unresected locally advanced head and neck squamous cell carcinoma (HNSCC) failed to meet the primary endpoint.
Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.
Sanofi has terminated a development agreement with Regulus in Alport syndrome, while Merck reaches the point of futility in a Phase III colorectal cancer trial.
JOBS
IN THE PRESS